Eli Lilly and Company $LLY Shares Purchased by Galvin Gaustad & Stein LLC

Key Points

• Galvin Gaustad & Stein LLC increased its Eli Lilly position by 347% in the third quarter, ending with 6,115 shares valued at approximately $7.08 million. Institutional investors and hedge funds collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with EPS of $8.38 beating estimates of $6.40 and revenue rising 47.7% year over year to $22.97 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $1,313.43.
• The company’s growth outlook is supported by its obesity, oncology and Alzheimer’s pipelines, including potential retatrutide growth and a planned $1 billion AI drug-discovery lab with Nvidia. However, the stock trades at a high valuation of roughly 39 times earnings and faces competition, pricing pressure and regulatory uncertainty in obesity treatments.

Galvin Gaustad & Stein LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 347.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,115 shares of the company's stock after buying an additional 4,747 shares during the period. Galvin Gaustad & Stein LLC's holdings in Eli Lilly and Company were worth $7,076,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $30,000. Maseco LLP increased its stake in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock worth $31,000 after acquiring an additional 28 shares during the period. Aventus Investment Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock worth $34,000 after purchasing an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on Eli Lilly (LLY) to $1,440 from $1,410 and maintained an “overweight” rating, implying substantial upside from recent trading levels. Cantor Fitzgerald price target report
• Positive Sentiment: Lilly and Nvidia committed up to $1 billion to establish an artificial-intelligence drug-discovery laboratory. The initiative could improve research efficiency and strengthen Lilly’s future pipeline, although financial benefits are likely long term. Nvidia and Eli Lilly AI drug discovery lab
• Positive Sentiment: Investor commentary remains bullish on Lilly’s growth beyond Mounjaro and Zepbound, highlighting retatrutide, manufacturing expansion, oncology products and other pipeline opportunities. Retatrutide’s potential for greater weight loss could provide another major growth driver if late-stage trials and regulatory review succeed. Eli Lilly obesity business analysis
• Positive Sentiment: New early-stage studies are expanding Lilly’s obesity and Alzheimer’s pipelines, while its oncology portfolio—including Jaypirca, Inluriyo and Retevmo—could offset slower growth from mature products. Lilly obesity drug trial
• Neutral Sentiment: Lilly signed a research collaboration and licensing agreement with InnoCare Pharma covering as many as five drug targets. The deal broadens potential discovery opportunities, but the targets remain early-stage and do not yet provide near-term revenue visibility. InnoCare and Eli Lilly deal
• Negative Sentiment: LLY remains valued at roughly 40 times trailing earnings, leaving the shares sensitive to slowing growth, pricing pressure and stronger competition in the GLP-1 market. Recent commentary argues the long-term opportunity is attractive but acknowledges that expectations are already high.
• Negative Sentiment: New WHO childhood-obesity guidance may increase scrutiny around the use, access and long-term safety of obesity medicines, creating regulatory and reimbursement uncertainty for Lilly and Novo Nordisk. WHO childhood obesity guidelines

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,169.77 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a fifty day moving average of $1,173.78 and a two-hundred day moving average of $1,096.45. The stock has a market capitalization of $1.10 trillion, a PE ratio of 39.25, a P/E/G ratio of 1.46 and a beta of 0.46. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on LLY shares. HSBC upped their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a report on Thursday, September 10th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a "buy" rating in a report on Thursday, September 17th. Royal Bank Of Canada upped their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 8th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $1,313.43.

Insider Buying and Selling

In related news, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.